The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.

Inclusion Criteria:

• Elevated fasting TGs and RC
• Elevated nonfasting TGs and RC
• Fasting LDL-C ≥ 50 mg/dL (≥ 1.29 mmol/L) and ≤ 130 mg/dL (≤ 3.36 mmol/L)
• Willingness to provide informed consent and comply with the intervention and all study assessments
• Stable diet for a minimum of 3 months prior to screening and with no plans to change during screening or trial participation
• Stable drug regimen (if relevant) prior to screening visit and no planned changes during screening or trial participation

Exclusion Criteria:

• Acute or chronic liver disease
• TG concentration ≥880mg/dl
• History of type 1 diabetes mellitus or history of diabetic ketoacidosis
• Newly diagnosed T2DM
• Participants with known active hepatitis A, B, or C
• Uncontrolled hypothyroidism
• Any condition that prevents the participant from complying with study procedures